Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11777191rdf:typepubmed:Citationlld:pubmed
pubmed-article:11777191lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C1518419lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C0003123lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C0065879lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C0043096lld:lifeskim
pubmed-article:11777191lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:11777191pubmed:issue1lld:pubmed
pubmed-article:11777191pubmed:dateCreated2002-1-4lld:pubmed
pubmed-article:11777191pubmed:abstractTextMegestrol acetate improves appetite and abrogates weight loss in some patients with advanced cancer. Moreover, preliminary studies suggest that progestational agents down-regulate interleukin-6 (IL-6), an inflammatory cytokine widely implicated in cancer-associated anorexia and weight loss. The present investigation examined the effects of megestrol acetate on IL-6 in an attempt to confirm these earlier, preliminary studies. The translational component of a large multi-institutional trial, this investigation examined 85 patients with advanced cancer and weight loss. Patients had been randomly assigned to receive megestrol acetate liquid suspension 800 mg/day + placebo tablets, or oral dronabinol tablets 2.5 mg b.i.d. + liquid placebo, or both agents. Other testing included serial physician-reported weight and patient-reported appetite and global quality of life. We found no significant differences in 1-month changes in serum IL-6 according to whether patients had been treated with megestrol acetate, dronabinol, or the combination: the mean differences +/- standard deviation were -1.52+/-4.7 pg/ml, -0.62+/-3.5 pg/ml, and -0.2+/-3.1 pg/ml, respectively (P=0.40, by one-way ANOVA). Among the patients who noted alterations in their appetite over 1 month, we observed no significant changes in IL-6. Finally, changes in serum IL-6 were not associated with shifts in weight or global quality of life. Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss.lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:languageenglld:pubmed
pubmed-article:11777191pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:citationSubsetIMlld:pubmed
pubmed-article:11777191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11777191pubmed:statusMEDLINElld:pubmed
pubmed-article:11777191pubmed:monthJanlld:pubmed
pubmed-article:11777191pubmed:issn0941-4355lld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:SloanJeff AJAlld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:JatoiAminahAlld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:YamashitaJun-...lld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:NovotnyPaul...lld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:WindschitlHar...lld:pubmed
pubmed-article:11777191pubmed:authorpubmed-author:LoprinziCharl...lld:pubmed
pubmed-article:11777191pubmed:issnTypePrintlld:pubmed
pubmed-article:11777191pubmed:volume10lld:pubmed
pubmed-article:11777191pubmed:ownerNLMlld:pubmed
pubmed-article:11777191pubmed:authorsCompleteYlld:pubmed
pubmed-article:11777191pubmed:pagination71-5lld:pubmed
pubmed-article:11777191pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:meshHeadingpubmed-meshheading:11777191...lld:pubmed
pubmed-article:11777191pubmed:year2002lld:pubmed
pubmed-article:11777191pubmed:articleTitleDoes megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation.lld:pubmed
pubmed-article:11777191pubmed:affiliationMayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. Jatoi.aminah@mayo.edulld:pubmed
pubmed-article:11777191pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11777191pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11777191pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11777191pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11777191pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:11777191pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11777191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11777191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11777191lld:pubmed